Abstract The 11th Acromegaly Consensus Conference in April 2017 was convened to
update recommendations on therapeutic outcomes for patients with acromegaly. Consensus …

Growth hormone-secreting pituitary adenomas that cause acromegaly arise as monoclonal
expansions of differentiated somatotroph cells and are usually sporadic. They are almost …

Objective: The aim was to formulate clinical practice guidelines for acromegaly. Participants:
The Task Force included a chair selected by the Endocrine Society Clinical Guidelines …

The growth hormone receptor (GHR), although most well known for regulating growth, has
many other important biological functions including regulating metabolism and controlling …

Secretion of growth hormone (GH), and consequently that of insulin-like growth factor 1 (IGF-
1), declines over time until only low levels can be detected in individuals aged≥ 60 years …

Abstract In March 2013, the Acromegaly Consensus Group met to revise and update
guidelines for the medical treatment of acromegaly. The meeting comprised experts skilled …

The WHO categorizes pituitary tumours as typical adenomas, atypical adenomas and
pituitary carcinomas, with typical adenomas constituting the major class. However, the WHO …

Abstract In March 2011, the Acromegaly Consensus Group met to revise and update the
guidelines on the diagnosis and treatment of acromegaly complications. The meeting was …

Pituitary adenomas are one of the most frequent intracranial tumors and occur with a
prevalence of approximately 1: 1000 in the developed world. Pituitary adenomas have a …

Abstract Angiotensin (Ang)-(1–7) is now recognized as a biologically active component of
the renin–angiotensin system (RAS). Ang-(1–7) appears to play a central role in the RAS …